Skip to content

NIV-NAVA vs NIV-PS/PC in Respiratory Insufficiency

Non-Invasive Ventilation With Neurally Adjusted Ventilatory Assist vs NIV Pressure Support or Pressure Control in Treatment of Patients With Acute Respiratory Insufficiency. A Prospective, Randomised, Single Blinded, Crossover Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02592512
Enrollment
30
Registered
2015-10-30
Start date
2015-10-31
Completion date
2017-04-30
Last updated
2017-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Insufficiency, Acute Respiratory Insufficiency

Keywords

Hypoxia, hypercapnia

Brief summary

This study evaluates the difference between Non Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NIV-NAVA) and Conventional Non Invasive Ventilation with Pressure Support (PS) or Pressure Control (PC). All the patients are ventilated in each mode for 4 hours. Afterwards they will be subjected to a semi-structured interview where they will be asked to compare the two modes. The hypothesis is that NIV-NAVA will correct patients power of Hydrogen (pH), PaCO2 og PaO2 more quickly than NIV-PS and NIV-NAVA is more comfortable for the patients.

Detailed description

Neurally Adjusted Ventilatory Assist (NAVA) is a ventilation mode where the diaphragm is controlling the amount of ventilatory assistance proportionally through a nasogastric tube containing electrodes which are sending the electrical activities of the diaphragm (Eadi) to the ventilator. Whereas Conventional ventilation modes like Pressure support or Pressure Control are dependent on the pressure drop or flow reversal to initiate assist delivered to the patient. This is last step of the signal chain leading to inhalation and is subject to disturbances such as intrinsic positive expiratory end pressure (PEEP), hyperinflation and leakage.

Interventions

Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

OTHERNIV-PS/PC

Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

Sponsors

Vejle Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted at the ICU with acute respiratory insufficiency and therefore have hypoxia(PaO2 \< 7 kPa on atmospheric air) og pH \< 7.35 with non-compensated hypercapnia (PaCO2 \> 6.0 kPa). * Patients, which according to the departments guidelines are required to treatment with NIV

Exclusion criteria

* Patients under years of 18. * Patients without the possibility to give informed consent. * Patients with neuromuscular or neurological disease. * Patients with a verified or suspected head trauma. * Patients with a acknowledged hiatus hernia. * Patients with an active or suspected active upper GI bleeding. * Patients which have previously been in the study. * Patients with a suspected or verified acute coronary syndrome.

Design outcomes

Primary

MeasureTime frame
Time for normalizing of Partial pressure of Oxygen (pO2) in arterial blood gases. Normal frame for pO2 7-14,4 (or to the usual level for the patient).8 hours
Time for normalizing of Power of Hydrogen (pH) in arterial blood gases. Normal pH frame 7.35-7.45.8 hours
Time for normalizing Carbon dioxide partial pressure (pCO2) in arterial blood gases. Normal frames pCO2 4,7-6,4 (or to the usual level for the patient).8 hours
Electrical activity of the diaphragm (Eadi). Reduction in respiratory work assessed by Eadi (in percentage).8 hours

Secondary

MeasureTime frameDescription
Patient comfort24 hoursThere will be conducted a semi-interview on the subjects. They will be asked: If they felt any difference in breathing between the two modes. If yes, what was the difference? Which method did you prefer? And why? Do you have any comments?

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026